These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21727754)

  • 21. Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro.
    Naritomi Y; Terashita S; Kagayama A; Sugiyama Y
    Drug Metab Dispos; 2003 May; 31(5):580-8. PubMed ID: 12695346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of human pharmacokinetics--improving microsome-based predictions of hepatic metabolic clearance.
    Fagerholm U
    J Pharm Pharmacol; 2007 Oct; 59(10):1427-31. PubMed ID: 17910819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches.
    Ito K; Houston JB
    Pharm Res; 2005 Jan; 22(1):103-12. PubMed ID: 15771236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of UDP-glucuronosyltransferase catalyzed formation of Picroside II glucuronide in microsomes of different species and recombinant UGTs.
    Li T; Zheng Y; Fu F; Ji H; Chen X; Zhao Y; Zhao D; Li N; Zhang L
    Xenobiotica; 2011 Jul; 41(7):530-7. PubMed ID: 21524190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of UDP-sugars, UDP and Mg
    Walia G; Smith AD; Riches Z; Collier AC; Coughtrie MWH
    Xenobiotica; 2018 Sep; 48(9):882-890. PubMed ID: 28868965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Species differences in UDP-glucuronosyltransferase activities in mice and rats.
    Shiratani H; Katoh M; Nakajima M; Yokoi T
    Drug Metab Dispos; 2008 Sep; 36(9):1745-52. PubMed ID: 18505787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of human pharmacokinetics--evaluation of methods for prediction of hepatic metabolic clearance.
    Fagerholm U
    J Pharm Pharmacol; 2007 Jun; 59(6):803-28. PubMed ID: 17637173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The glucuronidation of R- and S-lorazepam: human liver microsomal kinetics, UDP-glucuronosyltransferase enzyme selectivity, and inhibition by drugs.
    Uchaipichat V; Suthisisang C; Miners JO
    Drug Metab Dispos; 2013 Jun; 41(6):1273-84. PubMed ID: 23554428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences between human and rat intestinal and hepatic bisphenol A glucuronidation and the influence of alamethicin on in vitro kinetic measurements.
    Mazur CS; Kenneke JF; Hess-Wilson JK; Lipscomb JC
    Drug Metab Dispos; 2010 Dec; 38(12):2232-8. PubMed ID: 20736320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast.
    Oda S; Fujiwara R; Kutsuno Y; Fukami T; Itoh T; Yokoi T; Nakajima M
    Drug Metab Dispos; 2015 Jun; 43(6):812-8. PubMed ID: 25834030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin.
    Fisher MB; Campanale K; Ackermann BL; VandenBranden M; Wrighton SA
    Drug Metab Dispos; 2000 May; 28(5):560-6. PubMed ID: 10772635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of human UDP-glucuronosyltransferase isoforms involved in the isofraxidin glucuronidation and assessment of the species differences of the reaction.
    Meng F; Li Y; He G; Ge G; Liu S
    Fitoterapia; 2017 Mar; 117():118-125. PubMed ID: 27915055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
    Nakamori F; Naritomi Y; Hosoya K; Moriguchi H; Tetsuka K; Furukawa T; Kadono K; Yamano K; Terashita S; Teramura T
    Drug Metab Dispos; 2012 Sep; 40(9):1771-7. PubMed ID: 22685216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam.
    Carlile DJ; Zomorodi K; Houston JB
    Drug Metab Dispos; 1997 Aug; 25(8):903-11. PubMed ID: 9280396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse.
    Al Saabi A; Allorge D; Sauvage FL; Tournel G; Gaulier JM; Marquet P; Picard N
    Drug Metab Dispos; 2013 Mar; 41(3):568-74. PubMed ID: 23230132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases.
    Chang Y; Moody DE
    Drug Metab Lett; 2009 Apr; 3(2):101-7. PubMed ID: 19601871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altered AZT (3'-azido-3'-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment.
    Engtrakul JJ; Foti RS; Strelevitz TJ; Fisher MB
    Drug Metab Dispos; 2005 Nov; 33(11):1621-7. PubMed ID: 16049128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of hepatic microsomal intrinsic clearance and human clearance values for drugs.
    Nikolic K; Agababa D
    J Mol Graph Model; 2009 Oct; 28(3):245-52. PubMed ID: 19713138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for the intraluminal positioning of p-nitrophenol UDP-glucuronosyltransferase activity in rat liver microsomal vesicles.
    Fulceri R; Bánhegyi G; Gamberucci A; Giunti R; Mandl J; Benedetti A
    Arch Biochem Biophys; 1994 Feb; 309(1):43-6. PubMed ID: 8117111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug glucuronidation assays on human liver microsomes immobilized on microfluidic flow-through reactors.
    Kiiski I; Ollikainen E; Artes S; Järvinen P; Jokinen V; Sikanen T
    Eur J Pharm Sci; 2021 Mar; 158():105677. PubMed ID: 33309889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.